The specter of generic competition has long loomed above copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the outlook of similar medicinal investments. While early periods saw impressive gains, the exclusivity end has created the path for discounted substitutes, potentially reducing profitability and presenting a genuine d